Compare Stocks: IBIO, WHWK, EBS, and ANIK

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ANIK Anika Therapeutics	$20.84 -3.9%	$17.48	$8.37 ▼ $22.88	$278.84M	0.2	117,486 shs	171,472 shs
EBS Emergent Biosolutions	$5.96 -0.2%	$6.96	$4.36 ▼ $14.06	$305.62M	2.35	938,848 shs	1.30 million shs
IBIO iBio	$1.40 -2.1%	$1.50	$0.77 ▼ $3.82	$69.55M	1.3	1.20 million shs	374,471 shs
WHWK Whitehawk Therapeutics	$4.87 +0.6%	$4.25	$1.76 ▼ $5.49	$277.64M	0.76	319,020 shs	312,900 shs

7 Best Space Stocks to Own in 2026

The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ANIK Anika Therapeutics	+1.31%	+1.98%	+44.34%	+45.50%	+132.37%
EBS Emergent Biosolutions	+5.99%	+21.94%	-18.27%	-34.76%	-31.30%
IBIO iBio	-2.72%	-4.03%	-1.38%	-25.91%	+142,999,900.00%
WHWK Whitehawk Therapeutics	-4.72%	-0.62%	+30.81%	+1.26%	+167.40%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ANIK Anika Therapeutics	$20.84 -3.9%	$17.48	$8.37 ▼ $22.88	$278.84M	0.2	117,486 shs	171,472 shs
EBS Emergent Biosolutions	$5.96 -0.2%	$6.96	$4.36 ▼ $14.06	$305.62M	2.35	938,848 shs	1.30 million shs
IBIO iBio	$1.40 -2.1%	$1.50	$0.77 ▼ $3.82	$69.55M	1.3	1.20 million shs	374,471 shs
WHWK Whitehawk Therapeutics	$4.87 +0.6%	$4.25	$1.76 ▼ $5.49	$277.64M	0.76	319,020 shs	312,900 shs

7 Best Space Stocks to Own in 2026

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ANIK Anika Therapeutics	+1.31%	+1.98%	+44.34%	+45.50%	+132.37%
EBS Emergent Biosolutions	+5.99%	+21.94%	-18.27%	-34.76%	-31.30%
IBIO iBio	-2.72%	-4.03%	-1.38%	-25.91%	+142,999,900.00%
WHWK Whitehawk Therapeutics	-4.72%	-0.62%	+30.81%	+1.26%	+167.40%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ANIK Anika Therapeutics	2.75	Moderate Buy	$21.00	0.77% Upside
EBS Emergent Biosolutions	2.17	Hold	$10.00	67.76% Upside
IBIO iBio	3.13	Buy	$5.00	257.14% Upside
WHWK Whitehawk Therapeutics	2.63	Moderate Buy	$8.20	68.38% Upside

Current Analyst Ratings Breakdown

Latest IBIO, WHWK, EBS, and ANIK Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/21/2026	EBS Emergent Biosolutions	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (D-) ➝ Sell (D)
8/21/2026	EBS Emergent Biosolutions	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Underweight
8/11/2026	EBS Emergent Biosolutions	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold
8/10/2026	EBS Emergent Biosolutions	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$12.00 ➝ $10.00
8/7/2026	EBS Emergent Biosolutions	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
8/5/2026	ANIK Anika Therapeutics	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold ➝ Strong-Buy
7/30/2026	ANIK Anika Therapeutics	B. Riley Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$18.00 ➝ $21.00
7/30/2026	ANIK Anika Therapeutics	Barrington Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$21.00
7/13/2026	WHWK Whitehawk Therapeutics	Leerink Partners Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Outperform	$9.00
7/2/2026	IBIO iBio	Chardan Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$5.00
6/25/2026	WHWK Whitehawk Therapeutics	B. Riley Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$10.00

(Data available from 8/27/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ANIK Anika Therapeutics	$112.82M	2.47	N/A	N/A	$10.26 per share	2.03
EBS Emergent Biosolutions	$742.90M	0.41	$3.87 per share	1.54	$6.66 per share	0.90
IBIO iBio	$400K	173.88	N/A	N/A	$0.90 per share	1.56
WHWK Whitehawk Therapeutics	$7.14M	38.88	N/A	N/A	$3.21 per share	1.52

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ANIK Anika Therapeutics	-$10.88M	-$0.27	N/A	71.86	15.29	-3.14%	0.20%	0.15%	11/4/2026 (Estimated)
EBS Emergent Biosolutions	$52.60M	-$3.55	N/A	99.35	N/A	-22.95%	16.35%	6.17%	11/4/2026 (Estimated)
IBIO iBio	-$18.38M	-$0.58	N/A	N/A	N/A	N/A	-53.86%	-46.48%	9/4/2026 (Estimated)
WHWK Whitehawk Therapeutics	-$20.60M	-$1.12	N/A	N/A	N/A	N/A	-53.89%	-49.97%	N/A

Latest IBIO, WHWK, EBS, and ANIK Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
9/4/2026	Q4 2026	IBIO iBio	-$0.07	N/A	N/A	N/A	$0.08 million	N/A
8/6/2026	Q2 2026	WHWK Whitehawk Therapeutics	-$0.30	-$0.20	+$0.10	-$0.20	N/A	N/A
8/5/2026	Q2 2026	EBS Emergent Biosolutions	-$0.0850	$0.60	+$0.6850	-$3.49	$177.50 million	$234.30 million
7/29/2026	Q2 2026	ANIK Anika Therapeutics	$0.03	$0.42	+$0.39	$0.24	$29.21 million	$32.61 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ANIK Anika Therapeutics	N/A	N/A	N/A	N/A	N/A
EBS Emergent Biosolutions	N/A	N/A	N/A	N/A	N/A
IBIO iBio	N/A	N/A	N/A	N/A	N/A
WHWK Whitehawk Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ANIK Anika Therapeutics	N/A	4.48	3.19
EBS Emergent Biosolutions	1.70	5.42	2.95
IBIO iBio	N/A	11.88	11.88
WHWK Whitehawk Therapeutics	N/A	17.38	17.38

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ANIK Anika Therapeutics	91.53%
EBS Emergent Biosolutions	78.40%
IBIO iBio	7.90%
WHWK Whitehawk Therapeutics	52.08%

Insider Ownership

Company	Insider Ownership
ANIK Anika Therapeutics	12.08%
EBS Emergent Biosolutions	6.00%
IBIO iBio	2.75%
WHWK Whitehawk Therapeutics	49.90%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ANIK Anika Therapeutics	300	13.38 million	11.77 million	Optionable
EBS Emergent Biosolutions	2,420	51.27 million	48.20 million	Optionable
IBIO iBio	100	49.68 million	48.31 million	N/A
WHWK Whitehawk Therapeutics	21	57.01 million	28.56 million	N/A

IBIO, WHWK, EBS, and ANIK Headlines

Recent News About These Companies

Wall Street Analysts Predict a 47.64% Upside in Whitehawk Therapeutics, Inc. (WHWK): Here's What You Should Know

August 26 at 10:55 AM | zacks.com

1,341,394 Shares in Whitehawk Therapeutics, Inc. $WHWK Bought by ADAR1 Capital Management LLC

August 26 at 3:19 AM | marketbeat.com

Whitehawk Therapeutics, Inc. (NASDAQ:WHWK) Receives $8.20 Consensus PT from Brokerages

August 24 at 3:29 AM | americanbankingnews.com

Whitehawk Therapeutics, Inc. (NASDAQ:WHWK) Receives Consensus Recommendation of "Moderate Buy" from Brokerages

August 19, 2026 | marketbeat.com

Whitehawk Therapeutics Inc WHWK

August 14, 2026 | morningstar.comM

TD Cowen Remains a Hold on Whitehawk Therapeutics (WHWK)

August 10, 2026 | theglobeandmail.com

Whitehawk Therapeutics (NASDAQ:WHWK) Rating Increased to Hold at Wall Street Zen

August 8, 2026 | marketbeat.com

Whitehawk Therapeutics (NASDAQ:WHWK) Announces Quarterly Earnings Results, Beats Estimates By $0.10 EPS

August 6, 2026 | marketbeat.com

Whitehawk’s HWK-016 ADC Trial Advances in Tough Ovarian and Endometrial Cancers

August 6, 2026 | tipranks.com

Whitehawk Therapeutics Reports Second Quarter 2026 Financial Results and Recent Highlights

August 6, 2026 | prnewswire.com

Stempoint Capital LP Sells 519,438 Shares of Whitehawk Therapeutics, Inc. $WHWK

July 30, 2026 | marketbeat.com

Biocytogen and Whitehawk Therapeutics Enter Global Collaboration for Bispecific Antibody ADC Development

July 7, 2026 | businesswire.com

10 Hot Biotech Stocks Under $5 to Buy

June 10, 2026 | insidermonkey.com

Is Whitehawk Therapeutics (WHWK) One Of The Hot Biotech Stocks Under $5 To Buy?

June 10, 2026 | insidermonkey.com

Whitehawk Therapeutics Presents Realâ€‘World Analysis Confirming SEZ6 as a Highly Expressed, Clinically Relevant Target for SCLC and Other Neuroendocrine Tumors at ASCO 2026

May 30, 2026 | gurufocus.com

Whitehawk Therapeutics Presents Real‑World Analysis Confirming SEZ6 as a Highly Expressed, Clinically Relevant Target for SCLC and Other Neuroendocrine Tumors at ASCO 2026

May 30, 2026 | prnewswire.com

Whitehawk Therapeutics to Present at the Jefferies 2026 Global Healthcare Conference

May 28, 2026 | prnewswire.com

WHWK Stock Edges Up After Hours: Firm Boosts Pipeline Of Cancer Drugs On The Heels Of Capital Raise

May 21, 2026 | finance.yahoo.com

Whitehawk Therapeutics Expands ADC Pipeline with New Option Agreement for Use of CPT113 Linker-Payload

May 21, 2026 | prnewswire.com

Whitehawk Therapeutics to Participate in the TD Cowen 7th Annual Oncology Innovation Summit

May 20, 2026 | prnewswire.com

Whitehawk Therapeutics officer Ball sells $201k in stock

May 18, 2026 | investing.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

IBIO, WHWK, EBS, and ANIK Company Descriptions

Anika Therapeutics NASDAQ:ANIK

$20.84 -0.84 (-3.87%)

Closing price 04:00 PM Eastern

Extended Trading

$20.87 +0.03 (+0.14%)

As of 04:28 PM Eastern

Anika Therapeutics, Inc., a joint preservation company, creates and delivers advancements in early intervention orthopedic care in the areas of osteoarthritis (OA) pain management, regenerative solutions, sports medicine, and arthrosurface joint solutions in the United States, Europe, and internationally. The company develops, manufactures, and commercializes products based on hyaluronic acid (HA) technology platform. Its OA pain management products includes Monovisc and Orthovisc, an injectable HA-based viscosupplement for the pain relief from osteoarthritis conditions; and Cingal, a single-injection OA pain management product to provide both short- and long-term pain relief. The company's joint preservation and restoration product family comprises and orthopedic regenerative solutions, including Hyalofast and Tactoset; sports medicine solutions used to repair and reconstruct damaged ligaments and tendons; and preserving joint solutions, including partial joint replacement, joint resurfacing, and invasive and bone sparing implants, which are designed to treat upper and lower extremity orthopedic conditions. In addition, it offers non-orthopedic products comprising HA-based products for non-orthopedic applications including Hyvisc, a molecular weight injectable HA veterinary product; Hyalobarrier, an anti-adhesion barrier indicated for use after abdominal-pelvic surgeries; and Hyalomatrix used for the treatment of burns and ulcers, as well as products used for the treatment of ears, nose and throat disorders, and ophthalmic products. The company was founded in 1983 and is headquartered in Bedford, Massachusetts.

Emergent Biosolutions NYSE:EBS

$5.96 -0.01 (-0.15%)

Closing price 03:59 PM Eastern

Extended Trading

$5.95 -0.01 (-0.18%)

As of 06:10 PM Eastern

Emergent BioSolutions Inc., a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax. It also provides ACAM2000, a smallpox vaccine; CNJ-016 to address complications from smallpox vaccination; TEMBEXA for the treatment of smallpox disease caused by variola virus in adult and pediatric patients; BAT for the treatment of symptomatic botulism; Ebanga for the treatment of Ebola; Reactive Skin Decontamination Lotion Kit to remove or neutralize chemical warfare agents from the skin; Trobigard, a atropine sulfate obidoxime chloride auto-injector. In addition, the company is developing CGRD-001 for the treatment of poisoning by organophosphorus nerve agents or organophosphorus compounds; EBS-LASV to prevent Lassa fever; EBS-MARV to prevent Marburg virus disease; EBS-SUDV to prevent Sudan virus disease; Pan-Ebola mAbs for the treatment of ebola virus; SIAN Antidote for initial treatment of certain or suspected acute cyanide poisoning; UniFlu for immunity against influenza A and B viruses; and WEVEE-VLP for equine encephalitis virus infections. Further, it provides contract development and manufacturing services comprising drug substance and product manufacturing, and packaging, as well as technology transfer, process, and analytical development services. The company was incorporated in 1998 and is headquartered in Gaithersburg, Maryland.

iBio NASDAQ:IBIO

$1.40 -0.03 (-2.10%)

Closing price 04:00 PM Eastern

Extended Trading

$1.41 +0.01 (+0.71%)

As of 06:24 PM Eastern

iBio, Inc., a biotechnology company, provides contract development and manufacturing services to collaborators and third-party customers in the United States. The company operates in two segments: Biopharmaceuticals and Bioprocessing. Its lead therapeutic candidate is IBIO-100 that is being advanced for investigational new drug development for the treatment of systemic scleroderma and idiopathic pulmonary fibrosis. The company is also developing vaccine candidates comprising IBIO-200 and IBIO-201, which are in preclinical development for the prevention of severe acute respiratory syndrome coronavirus 2; and IBIO-400 for the treatment of classical swine fever. In addition, it is developing recombinant proteins for third parties on a catalog and custom basis; and offers a range of process development, manufacturing, filling and finishing, and bio analytic services. iBio, Inc. has a license agreement with Planet Biotechnology, Inc. to develop therapeutics for infectious diseases; collaboration agreement with The Texas A&M University System for the development of coronavirus disease 2019 vaccine candidates; license agreement with the University of Natural Resources and Life Sciences, Vienna; and collaboration agreement with CC-Pharming Ltd. The company is headquartered in Bryan, Texas.

Whitehawk Therapeutics NASDAQ:WHWK

$4.87 +0.03 (+0.62%)

Closing price 04:00 PM Eastern

Extended Trading

$4.86 0.00 (-0.10%)

As of 04:10 PM Eastern

Aadi Bioscience, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug candidate, FYARRO is a form of sirolimus bound to albumin. Aadi is evaluating FYARRO in cancers with known mTOR pathway activation, including tumor agnostic indications targeting specific genomic alterations that activate the mTOR pathway. The company was incorporated in 2007 and is headquartered in Pacific Palisades, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest IBIO, WHWK, EBS, and ANIK Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest IBIO, WHWK, EBS, and ANIK Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

IBIO, WHWK, EBS, and ANIK Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

IBIO, WHWK, EBS, and ANIK Company Descriptions

Anika Therapeutics NASDAQ:ANIK

Emergent Biosolutions NYSE:EBS

iBio NASDAQ:IBIO

Whitehawk Therapeutics NASDAQ:WHWK

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest IBIO, WHWK, EBS, and ANIK Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest IBIO, WHWK, EBS, and ANIK Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

IBIO, WHWK, EBS, and ANIK Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

IBIO, WHWK, EBS, and ANIK Company Descriptions

Anika Therapeutics NASDAQ:ANIK

Emergent Biosolutions NYSE:EBS

iBio NASDAQ:IBIO

Whitehawk Therapeutics NASDAQ:WHWK

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools